Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: C9

Gene summary for C9

Gene summary.

Gene information	Species	Human
	Gene symbol	C9
	Gene ID	735
	Gene name	complement C9
	Gene Alias	ARMD15
	Cytomap	5p13.1
	Gene Type	protein-coding
	GO ID	GO:0001906
	UniProtAcc	P02748

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
735	C9	HTA11_2487_2000001011	Human	Colorectum	SER	9.54e-07	2.54e-01	-0.1808
735	C9	HTA11_1938_2000001011	Human	Colorectum	AD	3.78e-11	4.19e-01	-0.0811
735	C9	HTA11_347_2000001011	Human	Colorectum	AD	1.84e-04	1.79e-01	-0.1954
735	C9	HTA11_2112_2000001011	Human	Colorectum	SER	6.32e-08	4.67e-01	-0.2196
735	C9	HTA11_3361_2000001011	Human	Colorectum	AD	3.81e-04	2.55e-01	-0.1207
735	C9	HTA11_83_2000001011	Human	Colorectum	SER	1.88e-09	3.58e-01	-0.1526
735	C9	HTA11_696_2000001011	Human	Colorectum	AD	3.67e-25	4.64e-01	-0.1464
735	C9	HTA11_866_2000001011	Human	Colorectum	AD	1.58e-09	2.35e-01	-0.1001
735	C9	HTA11_1391_2000001011	Human	Colorectum	AD	8.58e-12	3.53e-01	-0.059
735	C9	HTA11_5216_2000001011	Human	Colorectum	SER	2.74e-05	3.76e-01	-0.1462
735	C9	HTA11_546_2000001011	Human	Colorectum	AD	3.93e-02	2.02e-01	-0.0842
735	C9	HTA11_7663_2000001011	Human	Colorectum	SER	3.70e-02	2.97e-01	0.0131
735	C9	HTA11_7696_3000711011	Human	Colorectum	AD	9.91e-03	1.09e-01	0.0674
735	C9	HTA11_6818_2000001011	Human	Colorectum	AD	4.15e-06	4.13e-01	0.0112
735	C9	HTA11_6818_2000001021	Human	Colorectum	AD	2.40e-10	4.06e-01	0.0588
735	C9	HTA11_99999970781_79442	Human	Colorectum	MSS	1.67e-02	1.12e-01	0.294
735	C9	HTA11_99999971662_82457	Human	Colorectum	MSS	1.78e-05	1.89e-01	0.3859
735	C9	HTA11_99999974143_84620	Human	Colorectum	MSS	3.09e-04	1.73e-01	0.3005

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00346612	Oral cavity	OSCC	ncRNA catabolic process	28/7305	43/18723	4.71e-04	2.79e-03	28
GO:0070933	Oral cavity	OSCC	histone H4 deacetylation	10/7305	11/18723	5.78e-04	3.30e-03	10
GO:00083618	Oral cavity	OSCC	regulation of cell size	92/7305	181/18723	7.86e-04	4.26e-03	92
GO:00991113	Oral cavity	OSCC	microtubule-based transport	96/7305	190/18723	7.92e-04	4.27e-03	96
GO:00480086	Oral cavity	OSCC	platelet-derived growth factor receptor signaling pathway	34/7305	56/18723	8.17e-04	4.35e-03	34
GO:000632510	Oral cavity	OSCC	chromatin organization	190/7305	409/18723	1.17e-03	5.97e-03	190
GO:003003819	Oral cavity	OSCC	contractile actin filament bundle assembly	57/7305	106/18723	1.42e-03	6.84e-03	57
GO:004314919	Oral cavity	OSCC	stress fiber assembly	57/7305	106/18723	1.42e-03	6.84e-03	57
GO:004592710	Oral cavity	OSCC	positive regulation of growth	125/7305	259/18723	1.44e-03	6.97e-03	125
GO:001063418	Oral cavity	OSCC	positive regulation of epithelial cell migration	88/7305	176/18723	1.91e-03	8.94e-03	88
GO:002261214	Oral cavity	OSCC	gland morphogenesis	62/7305	118/18723	1.91e-03	8.94e-03	62
GO:003223119	Oral cavity	OSCC	regulation of actin filament bundle assembly	56/7305	105/18723	1.99e-03	9.23e-03	56
GO:00342495	Oral cavity	OSCC	negative regulation of cellular amide metabolic process	130/7305	273/18723	2.20e-03	1.00e-02	130
GO:00434916	Oral cavity	OSCC	protein kinase B signaling	103/7305	211/18723	2.29e-03	1.02e-02	103
GO:00022243	Oral cavity	OSCC	toll-like receptor signaling pathway	63/7305	121/18723	2.36e-03	1.04e-02	63
GO:00605378	Oral cavity	OSCC	muscle tissue development	185/7305	403/18723	2.60e-03	1.14e-02	185
GO:00160751	Oral cavity	OSCC	rRNA catabolic process	15/7305	21/18723	2.65e-03	1.16e-02	15
GO:00703735	Oral cavity	OSCC	negative regulation of ERK1 and ERK2 cascade	43/7305	78/18723	2.80e-03	1.22e-02	43
GO:00027646	Oral cavity	OSCC	immune response-regulating signaling pathway	212/7305	468/18723	2.93e-03	1.27e-02	212
GO:00516454	Oral cavity	OSCC	Golgi localization	11/7305	14/18723	3.09e-03	1.33e-02	11

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05020	Colorectum	AD	Prion disease	133/2092	273/8465	2.47e-18	8.29e-17	5.29e-17	133
hsa05171	Colorectum	AD	Coronavirus disease - COVID-19	113/2092	232/8465	9.90e-16	2.55e-14	1.63e-14	113
hsa04810	Colorectum	AD	Regulation of actin cytoskeleton	75/2092	229/8465	3.36e-03	1.76e-02	1.12e-02	75
hsa050201	Colorectum	AD	Prion disease	133/2092	273/8465	2.47e-18	8.29e-17	5.29e-17	133
hsa051711	Colorectum	AD	Coronavirus disease - COVID-19	113/2092	232/8465	9.90e-16	2.55e-14	1.63e-14	113
hsa048101	Colorectum	AD	Regulation of actin cytoskeleton	75/2092	229/8465	3.36e-03	1.76e-02	1.12e-02	75
hsa050202	Colorectum	SER	Prion disease	119/1580	273/8465	4.61e-22	3.06e-20	2.22e-20	119
hsa048102	Colorectum	SER	Regulation of actin cytoskeleton	60/1580	229/8465	2.74e-03	2.02e-02	1.47e-02	60
hsa050203	Colorectum	SER	Prion disease	119/1580	273/8465	4.61e-22	3.06e-20	2.22e-20	119
hsa048103	Colorectum	SER	Regulation of actin cytoskeleton	60/1580	229/8465	2.74e-03	2.02e-02	1.47e-02	60
hsa050204	Colorectum	MSS	Prion disease	129/1875	273/8465	1.04e-20	5.00e-19	3.06e-19	129
hsa051714	Colorectum	MSS	Coronavirus disease - COVID-19	108/1875	232/8465	6.50e-17	1.67e-15	1.03e-15	108
hsa048104	Colorectum	MSS	Regulation of actin cytoskeleton	68/1875	229/8465	4.27e-03	1.86e-02	1.14e-02	68
hsa050205	Colorectum	MSS	Prion disease	129/1875	273/8465	1.04e-20	5.00e-19	3.06e-19	129
hsa051715	Colorectum	MSS	Coronavirus disease - COVID-19	108/1875	232/8465	6.50e-17	1.67e-15	1.03e-15	108
hsa048105	Colorectum	MSS	Regulation of actin cytoskeleton	68/1875	229/8465	4.27e-03	1.86e-02	1.14e-02	68

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SNV

Missense_Mutation

c.706N>C

p.Asn236His

p.N236H

P02748

protein_coding

deleterious(0.03)

benign(0.005)

TCGA-A2-A0EW-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

SNV

Missense_Mutation

novel

c.1150N>A

p.His384Asn

p.H384N

P02748

protein_coding

tolerated(1)

benign(0)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SNV

Missense_Mutation

novel

c.1483N>C

p.Glu495Gln

p.E495Q

P02748

protein_coding

deleterious(0.03)

probably_damaging(0.989)

TCGA-BH-A0B0-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

SNV

Missense_Mutation

c.1280C>T

p.Ser427Leu

p.S427L

P02748

protein_coding

deleterious(0.02)

possibly_damaging(0.879)

TCGA-BH-A2L8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

SNV

Missense_Mutation

c.163N>T

p.Asp55Tyr

p.D55Y

P02748

protein_coding

deleterious(0.02)

probably_damaging(0.996)

TCGA-PE-A5DE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

insertion

Frame_Shift_Ins

novel

c.6_7insT

p.Ala3CysfsTer26

p.A3Cfs*26

P02748

protein_coding

TCGA-A2-A04V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

insertion

In_Frame_Ins

novel

c.5_6insCTGGGACTACCATAACAAAGCACCACAAGCTGG

p.Ser2_Ala3insTrpAspTyrHisAsnLysAlaProGlnAlaGly

p.S2_A3insWDYHNKAPQAG

P02748

protein_coding

TCGA-A2-A04V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

deletion

Frame_Shift_Del

c.1481delN

p.Leu494TrpfsTer14

p.L494Wfs*14

P02748

protein_coding

TCGA-AO-A03V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

fluorouracil

insertion

Nonsense_Mutation

novel

c.122_123insGTGAGGATGCTGAGGATGACTGCGGAA

p.Ile41delinsMetTerGlyCysTerGlyTerLeuArgLys

p.I41delinsM*GC*G*LRK

P02748

protein_coding

TCGA-BH-A0HK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

SNV

Missense_Mutation

novel

c.1294G>A

p.Gly432Arg

p.G432R

P02748

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-C5-A8XI-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1